This is a Technical Analysis on Moderna (MRNA) on the 1 Week Timeframe.
Current price action shows that we are currently in the process of breaking a MAJOR SUPPORT Zone.
We held critical SUPPORT multiple times ABOVE the $115.00 level, for a span of about 26 months. Expressed by the GREEN circles. But notice we havent been able to successfully rally and stay...
FULC on the 15 minute chart had a good response to favorable earnings and then retraced.
It is now bounding off the Fib 0.5 level and also confluent with the POC line of the volume
profile and the mean of the anchored VWAP. Buying volume appropriately overtook selling
volume on the reversal Luxalgo's Echo indicator, an AI predictive tool, suggests a 10%...
Applied Therapeutics is an uptrending biotechnology company that has earnings
in prior quarters and is heading into another earnings report about may 11th.
The run up in price cction is largely on the proposition of future growth much
like TSLA back in the day.
On the chart besides the obvious uptrend, the volume indicator shows a dramatic
volume surge...
As shown on the daily chart dating back to last summer SIGA has been on a persistent decline since the cooling down from the parabolic
breakout last summer. Is there a repeat in the picture? Fundamentally, earnings continue to be weak. much of the stock is held by insiders and
the whole monkey pox thing is settled down although the main product may have use...
NVAX as seen on the weekly chart has been in price distress for a long time.
It has only one product on the market due to various issues with the FDA process.
It has a variety of products in development as linked below.
The question is whether it will run out of cash before a sustained revenue
stream develops. FDA approvals for the pipeline products could take...
3/16/23 - Enzo Biochem (ENZ) stock is rising higher on an asset sale agreement.
It’s selling its Clinical Laboratory division to Labcorp (LH).
3/20/23 - Monthly GD on MC.
8/23/23 - $3 per share.
I've become interested in BZYR which trades only OTC at this time. Why is this OTC stock of high importance for long term investors? In order to set this out my post is broken into various parts:
1 - Introduction
2 - The historical battles
3 - Efficacy of a cancer treatment
4 - Summary
5 - The risk to reward for long term investors.
The above cannot possibly...
Will it pull up the
AdvisorShares Psychedelics ETF?
Strength in the #Biotech sector would also be a friendly situation.
here are the top holdings:
CMPS COMPASS PATHWAYS PLC 13.12%
ATAI ATAI LIFE SCIENCES NV 9.73%
CYBN CYBIN INC 7.97%
SEEL SEELOS THERAPEUTICS INC 6.90%
ITCI INTRA-CELLULAR THERAPIES INC 6.44%
HUGE FSD PHARMA INC-CLASS B 5.82%
SAGE SAGE...
Biotechnology is the favorite sector of one of our analysts, most of his portfolio consists of biotechs, and he himself claims that it is the cryptocurrency of the common stock market.
Why? Let's explain :
High risk/reward and high volatility.
Imagine this: you invest in a company that has no revenue or any specific product, yet you believe in the idea it...
ABBV is one of Warren Buffet’s holding in BRK.B. It has been respecting the weekly wma50 for a long time while holding an uptrend.
I think the sentiment has been too bearish & a shortterm rebound in the general market is due in the next few days.
Not trading advice.3
AMEX:LABU
LABU a 3x leveraged EFT in the biotechnology sector has diverse holdings.
My thesis is that biotechnology and healthcare are relatively unhinged from the broader general market.
On this 15 minute chart, consolidation at support is seen in July, Price then rapidly rose
into a triple top in mid-August followed by a descent into a double bottom at...
Argenx is another biotech stock setting up in a textbook breakout pattern.
Shares traded up through resistance Monday morning on good volume, but the move was ultimately held back by a nasty overall market.
ARGX still held up well, and will likely continue its advance higher.
MRNA has rallied 66% from its bottom set in mid june.
Technical indicators suggest a strong turnaround.
The P/E ratio and Forward P/E ratio remain in the low single digits.
I boosted my position when the price crossed above the 50 day EMA.
I will take advantage of any pull-back below the 200 day EMA close or low.
Overall, this is still a nice entry point if...
by @newsfile on 2 Aug 2022, 03:15
Breakthrough Discovery: AccuTOX(TM) Effectively Kills Cancer Cells by Directly Eliciting DNA Damage
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development...
Setup was nice. I missed the entry, no FOMO. Must now patiently wait for price to tighten up. There will always be a next train.
Risk: 90 bps
You don't need to know what's going to happen next to make money ~Mark Douglas
Anything can happen ~Mark Douglas
